BAYN.DE - Bayer Aktiengesellschaft

XETRA - XETRA Delayed price. Currency in EUR
106.50
+1.40 (+1.33%)
At close: 5:35PM CET
Stock chart is not supported by your current browser
Previous close105.10
Open104.90
Bid0.00 x 28400
Ask0.00 x 2100
Day's range104.70 - 106.50
52-week range97.12 - 123.90
Volume6,184,479
Avg. volume1,930,588
Market cap88.121B
BetaN/A
PE ratio (TTM)12.08
EPS (TTM)8.82
Earnings date28 Feb 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est120.91
  • Reuters - UK Focus4 days ago

    EU mergers and takeovers (Dec 13)

    The following are mergers under review by the European Commission and a brief guide to the EU merger process: APPROVALS AND WITHDRAWALS -- British budget carrier easyJet to acquire parts of German airline ...

  • EU regulators to warn Bayer about Monsanto bid: source
    Reuters9 days ago

    EU regulators to warn Bayer about Monsanto bid: source

    EU antitrust regulators are set to warn Bayer its planned purchase of U.S. seed maker Monsanto may hurt competition, a person familiar with the matter said on Friday, a move that would force Bayer to offer concessions to address the concerns. The $66 billion deal would make Bayer (BAYGn.DE) the world's largest pesticides and seeds company, an outcome already facing strong criticism from environmentalists and some farm groups. The European Commission is expected to send a charge sheet known as a statement of objections to the companies in the coming weeks, but a final decision has not yet been made, the person said.

  • EU regulators to warn Bayer about Monsanto bid -source
    Reuters9 days ago

    EU regulators to warn Bayer about Monsanto bid -source

    EU antitrust regulators are set to warn Bayer its planned purchase of U.S. seed maker Monsanto may hurt competition, a person familiar with the matter said on Friday, a move that would force Bayer to offer concessions to address the concerns. The $66 billion deal would make Bayer (BAYGn.DE) the world's largest pesticides and seeds company, an outcome already facing strong criticism from environmentalists and some farm groups. The European Commission is expected to send a charge sheet known as a statement of objections to the companies in the coming weeks, but a final decision has not yet been made, the person said.

  • Reuters - UK Focus10 days ago

    EU mergers and takeovers (Dec 8)

    The following are mergers under review by the European Commission and a brief guide to the EU merger process: APPROVALS AND WITHDRAWALS -- France's Engie, Omnes Capital and Predica Prevoyance to jointly ...

  • Bayer to Face EU Objections to Monsanto Deal in Coming Days
    Bloomberg10 days ago

    Bayer to Face EU Objections to Monsanto Deal in Coming Days

    Bayer AG is set to get a so-called statement of objections cataloging potential reasons for the European Union’s antitrust regulator to block its proposed $66 billion takeover of Monsanto Co. as soon as ...

  • Reuters11 days ago

    EU mergers and takeovers (Dec 6)

    BRUSSELS, Dec 6 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process: APPROVALS AND WITHDRAWALS -- China's COSCO Shipping to acquire ...

  • Reuters12 days ago

    Jury orders Bayer, Johnson & Johnson to pay $28 million in Xarelto lawsuit

    The jury slapped the companies, which jointly developed the blockbuster drug, with $1.8 million in compensatory and $26 million in punitive damages, according to the couple's lawyer. The verdict marks the first trial loss in litigation over Xarelto. Bayer and J&J have won three previous cases in federal court.

  • Jury orders Bayer, J&J to pay $28 million in Xarelto lawsuit
    Reuters12 days ago

    Jury orders Bayer, J&J to pay $28 million in Xarelto lawsuit

    The jury slapped the companies, which jointly developed the blood thinner, with $1.8 million in compensatory and $26 million in punitive damages, according to the couple's lawyer. The verdict marks the first trial loss in litigation over Xarelto. Bayer and J&J have won three previous cases in federal court.

  • J&J, Bayer Ordered to Pay $28 Million in First Xarelto Loss
    Bloomberg13 days ago

    J&J, Bayer Ordered to Pay $28 Million in First Xarelto Loss

    Johnson & Johnson and Bayer AG are responsible for a woman’s injuries tied to the blood-thinning drug Xarelto and must pay more than $29 million in damages, jurors concluded in the companies’ first loss ...

  • Market Realist14 days ago

    How Regeneron Pharmaceuticals Performed in 3Q17

    In 3Q17, Regeneron Pharmaceuticals (REGN) generated revenue of $1.5 billion, which reflected ~23% growth year-over-year and ~2% growth quarter-over-quarter.

  • Market Realist16 days ago

    How UTHR’s Remodulin, Adcirca, and Unituxin Performed in 3Q17

    In 3Q17, United Therapeutics' (UTHR) Remodulin reported revenues of $187.3 million, which reflected ~23% growth on a year-over-year (or YoY) basis and ~19% growth on a quarter-over-quarter basis.

  • Business Wire17 days ago

    CFIUS Completes Review of Proposed Merger of Bayer and Monsanto

    Bayer and Monsanto (NYSE: MON) today announced that the Committee on Foreign Investment in the United States (“CFIUS”) has completed its review of the proposed merger, and has concluded that there are no unresolved national security concerns with respect to the transaction. The acquisition is subject to customary closing conditions, including receipt of required regulatory approvals. Bayer and Monsanto will continue to cooperate with the authorities in order to complete the transaction in early 2018.

  • Reuters - UK Focus18 days ago

    EU mergers and takeovers (Nov 30)

    The following are mergers under review by the European Commission and a brief guide to the EU merger process: APPROVALS AND WITHDRAWALS None NEW LISTINGS -- Private equity firm KKR and South Korean industrial ...

  • Market Realist19 days ago

    Nektar Therapeutics Sees Setbacks in Plans for Ciproflaxin DPI

    On November 16, 2017, the FDA's Antimicrobial Drugs Advisory Committee voted down the 14-day regimen and 28-day regimen of Nektar Therapeutics' ciprofloxacin DPI.

  • Bayer says antitrust reviews going into 'unimaginable depths'
    Reuters19 days ago

    Bayer says antitrust reviews going into 'unimaginable depths'

    The antitrust review of Bayer's planned takeover of Monsanto is going into "unimaginable depths," Bayer's Chief Executive Werner Baumann said on Wednesday, but added he remained confident that the deal would be closed early next year. "To illustrate the point, we have by now delivered more than 4 million pages of documents to the EU commission," Baumann told a conference. "The intention of cartel authorities, here and overseas, is that the antitrust remedies allow competitors ... to be comprehensively enabled over the long term," Baumann said.

  • Reuters - UK Focus21 days ago

    EU mergers and takeovers (Nov 27)

    The following are mergers under review by the European Commission and a brief guide to the EU merger process: APPROVALS AND WITHDRAWALS -- Deutsche Alternative Asset Management, which is an affiliate of ...

  • Reuters25 days ago

    EU mergers and takeovers (Nov 23)

    BRUSSELS, Nov 23 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process: APPROVALS AND WITHDRAWALS -- Apollo Capital Management to acquire ...

  • Reuters - UK Focus25 days ago

    EU mergers and takeovers (Nov 23)

    The following are mergers under review by the European Commission and a brief guide to the EU merger process: APPROVALS AND WITHDRAWALS -- Apollo Capital Management to acquire Dutch toy store chain Intertoys ...

  • Brazil pushes back decision on Bayer-Monsanto tie-up
    Reuters25 days ago

    Brazil pushes back decision on Bayer-Monsanto tie-up

    Brazilian antitrust agency Cade on Wednesday extended its deadline to review the takeover of Monsanto Co (MON.N) by Bayer AG (BAYGn.DE) by 90 days to late March, potentially spoiling plans to wrap up the $66 billion (£49.60 billion) tie-up by the end of the year. Bayer and Monsanto declined to comment on the decision. Brazil is Monsanto's biggest market outside of the United States.

  • Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo
    Zackslast month

    Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo

    Key highlights this week include the FDA approval of AstraZeneca's (AZN) severe asthma drug and Bayer's collaboration with Loxo for cancer.

  • Reuters - UK Focuslast month

    EU mergers and takeovers (Nov 15)

    The following are mergers under review by the European Commission and a brief guide to the EU merger process: APPROVALS AND WITHDRAWALS -- UK oil company BP and holding company Bridas Corp to acquire oil ...

  • Reuterslast month

    Bayer hires new blood to stem 'Amazon effect' in consumer health

    German drugmaker Bayer (BAYGn.DE) has hired the head of Nestle's (NESN.S) baby food business to help it reverse a drop in revenue from consumer health brands, which often fail to appeal to buyers on Amazon (AMZN.O) and other online platforms. Bayer has appointed Nestle's Heiko Schipper, 48, to run the Consumer Health division as a group board member from March 1 next year, replacing Erica Mann, Bayer said in a statement on Wednesday. Bayer was caught off guard by the speed of U.S. consumers switching to online stores at the expense of established drugstores.

  • Reuters - UK Focuslast month

    Bayer hires new blood to stem 'Amazon effect' in consumer health

    German drugmaker Bayer (Swiss: BAYN-EUR.SW - news) has hired the head of Nestle's baby food business to help it reverse a drop in revenue from consumer health brands, which often fail to appeal to buyers on Amazon and other online platforms. Bayer (IOB: 0P6S.IL - news) has appointed Nestle's Heiko Schipper, 48, to run the Consumer Health division as a group board member from March 1 next year, replacing Erica Mann, Bayer said in a statement on Wednesday.

  • This Cancer Biotech Is Falling On Its $1.55 Billion Bayer Deal
    Investor's Business Dailylast month

    This Cancer Biotech Is Falling On Its $1.55 Billion Bayer Deal

    Loxo toppled Tuesday after agreeing to codevelop two cancer therapies with drug firm Bayer.

  • From Bayer to Qualcomm, M&A Gets Costlier in the EU
    Bloomberglast month

    From Bayer to Qualcomm, M&A Gets Costlier in the EU

    If time is money, big M&A is getting a lot costlier in the European Union thanks to a tactic increasingly deployed by the bloc’s merger watchdogs in Brussels.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes